**Alu Deletions in LAMA2 and CDH4 Genes Are Key Components of Polygenic Predictors of Longevity**

Vera V. Erdman 1,* Denis D. Karimov 2, Ilsia A. Tuktarova 1, Yanina R. Timasheva 1,* Timur R. Nasibullin 1,* and Gulnaz F. Korytina 1

1 Institute of Biochemistry and Genetics, Subdivision of the Ufa Federal Research Centre of the Russian Academy of Sciences, 450054 Ufa, Russia
2 Ufa Research Institute of Labor Medicine and Human Ecology, 450106 Ufa, Russia
* Correspondence: danivera@mail.ru

**Abstract:** Longevity is a unique human phenomenon and a highly stable trait, characterized by polygenicity. The longevity phenotype occurs due to the ability to successfully withstand the age-related genomic instability triggered by Alu elements. The purpose of the cross-sectional study was to evaluate the combined contribution of *ACE*/*Ya5ACE*, *CDH4*/*Ya5NBC516*, *COL13A1*/*Ya5ac1986*, *HECW1*/*Ya5NBC182*, *LAMA2*/*Ya5-MLS19*, *PLAT*/*TPA25*, *PKHD1L1*/*Yb8AC702*, *SEMA6A*/*Ya5NBC597*, *STK38L*/*Ya5ac2145* and *TEAD1*/*Ya5ac2013* Alu elements to longevity. The study group included 2054 unrelated individuals aged from 18 to 113 years who are ethnic Tatars from Russia. We analyzed the dynamics of the allele and genotype frequencies of the studied Alu polymorphic loci in the age groups of young (18–44 years old), middle-aged (45–59 years old), elderly (60–74 years old), old seniors (75–89 years old) and long-livers (90–113 years old). Most significant changes in allele and genotype frequencies were observed between the long-livers and other groups. The search for polygenic predictors of longevity was performed using the APSampler program. Attaining longevity was associated with the combinations *LAMA2*/*ID + CDH4*/*D* (OR = 2.23, P<sub>Bonf</sub> = 1.90 × 10<sup>−2</sup>) and *CDH4*/*DD + LAMA2*/*ID + HECW1*/*D* (OR = 4.58, P<sub>Bonf</sub> = 9.00 × 10<sup>−5</sup>) among persons aged between 18 and 89 years, *LAMA2*/*ID + CDH4*/*D + SEMA6A*/*I* for individuals below 75 years of age (OR = 3.13, P<sub>Bonf</sub> = 2.00 × 10<sup>−2</sup>), *LAMA2*/*ID + HECW1*/*I* for elderly people aged 60 and older (OR = 3.13, P<sub>Bonf</sub> = 2.00 × 10<sup>−2</sup>) and *CDH4*/*DD + LAMA2*/*D + HECW1*/*D* (OR = 4.21, P<sub>Bonf</sub> = 2.60 × 10<sup>−5</sup>) and *CDH4*/*DD + LAMA2*/*D + ACE*/*I* (OR = 3.68, P<sub>Bonf</sub> = 1.90 × 10<sup>−2</sup>) among old seniors (75–89 years old). The key elements of combinations associated with longevity were the deletion alleles of *CDH4* and *LAMA2* genes. Our results point to the significance for human longevity of the Alu polymorphic loci in *CDH4*, *LAMA2*, *HECW1*, *SEMA6A* and *ACE* genes, involved in the integration systems.

**Keywords:** longevity; aging; Alu retrotransposon; polygenic predictor; APSampler

1. **Introduction**

Longevity is a sociobiological phenomenon of human life, characterized by the ability of individuals to keep their physiological parameters at a qualitatively high level for a long enough period of life and exceeding the life expectancy average for population. The longevity phenotype is obtained under the influence of hereditary, behavioral and environmental factors. Studying the role of heritability for longevity using the twin method shows a high percentage of the genetic factor—from 33% to 48% [1]. To date, a large number of age-associated genetic markers have been identified. This is facilitated by the enduring interest in longevity as one of the fundamental problems of humanity, as well as the modern technical capabilities of molecular genetics, which make it possible to conduct the whole-genome and whole-exome sequencing. At the same time, GWAS data demonstrated the functional heterogeneity of age-associated polymorphic genetic variants [2–4]. This provides a background for searching the markers of aging and longevity among a variety of signaling pathways within the framework of various hypotheses.
A functional analysis of a number of loci associated with age showed that one of the main causes of aging can be considered the absolute and relative number of lesions in the organism caused by damage in molecules, cells, organs and their systems [5]. In total, these disorders lead to a decrease in functional activity and a violation of homeostasis of the whole organism as well as its parts, without the possibility of complete recovery. Thus, an age-dependent increase in genome instability leads to a limitation in life expectancy and is involved in the manifestation of the frail phenotype. Accordingly, the ability of the system to adjust the optimal balance of the cellular processes to the intrinsic senile background of an aging organism favors the development of a long-lived phenotype.

Mobile genetic elements (MGEs) play a significant role among the endogenous factors of genome instability [6]. Alu elements are one of the most widespread MGE families in the human genome—the number of copies of these elements exceeds 1 million, which is about 11% of the entire DNA [6]. About 30% of all genes include the Alu insertion [7]. A family of Alu repeats belongs to a class of Short Interspersed Nucleotide Elements (SINE), which is included in the subgroup of non-LTR retrotransposons. Structural features and processes of Alu transposition are described in detail in the reviews [6–8].

MGE activity is often considered a common occurrence in the genome functioning and in the development of a biological system [9]. The ability of Alu-MGEs to function as enhancers, insulators and alternative splicing sites and participate in other processes in the cell probably explains their wide distribution and indicates the evolutionary advantage of their presence in the human genome [10]. MGE transpositions identified during embryonic development are involved in the regulation of cell and tissue differentiation, and also mediate widespread structural variations in human populations [11]. During the postnatal ontogenesis, activation of certain MGEs in stem cells is necessary for pluripotent maintenance as well as for specific cell differentiation. With age, MGEs can cause various mutations and chromosomal aberrations and affect the epigenetic landscape of the genome, transcription regulation processes and gene expression [7,12]. Thus, by profoundly changing the structure, expression and function of genes, they are involved in the triggering of various pathologies. For example, a recent study has shown the role of Alu in the genes of the angiotensin-converting enzyme (ACE) and the tissue-type plasminogen activator (PLAT) in susceptibility to infectious agents, such as SARS-CoV-2 [13]. Alu retrotransposons regulate the mechanisms of natural aging by participating in important cellular processes such as proliferation, apoptosis and stress reactions [14]. All this, in general, indicates the role of Alu-MGEs in the adaptation processes that are important for the attainment of the longevity phenotype.

Alu insertions from the young subfamilies Ya5 and Yb8 are the only members of the family that retained transpositional activity and therefore can influence the adaptive abilities of the organism. For our study, we selected the genes with AluYa5 and AluYb8 insertions in their introns, including the genes encoding transcription enhancer factor (TEAD1), serin/threonine kinase 38-like (STK38L), E3 ubiquitin-protein ligase (HECW1), polycystic kidney and hepatic disease 1-like protein 1 (PKHD1L1), cell receptor semaforin-6 (SEMA6A), R-cadherin adhesion protein (CDH4), collagen type 13 alpha 1 chain (COL13A1), laminin-2a (LAMA2), PLAT and ACE. Participating in the growth and development, control of metabolism, the immune response and apoptosis and being the blood plasma enzymes, components of extracellular matrix, as well as key transcription factors, these genes are interwoven and important for the physiological and pathological aging processes. Previous reports have linked the TEAD1, HECW1, SEMA6A, COL13A1 and LAMA2 genes with different age-related cancers [15–21], the PLAT and ACE genes with cardiovascular disease [22–25], the ACE and HECW1 genes with Alzheimer’s disease [25,26] and the SEMA6A gene with type 2 diabetes [27]. The STK38L and PKHD1L1 genes play an important role in the functioning of the immune system [28,29]. The ACE, PLAT and CDH4 genes were associated with aging and longevity [20,24,30–35].

Many genes exert pleiotropic effects, thus the same allelic variant of a gene can both contribute to longevity and counteract this phenotype, depending on concomitant factors
such as the genetic environment. This concept is of particular importance in terms of the role of Alu-MGEs in the end-of-life adaptation, because genetic architecture shaped by natural selection due to the species-specific arrangement of various MGEs relative to each other and protein-coding genes is fundamental for the systemic control of the genome functioning during ontogenesis [7]. Therefore, our research objective was to identify the combined contribution of ACE*Ya5ACE, CDH4*Yb8NBC516, COL13A1*Ya5ac1986, HECW1*Ya5NBC182, LAMA2*Ya5-MLS19, PLAT*TPA25, PKHD1L1*Yb8AC702, SEMA6A*Yb8NBC597, STK38L*Ya5ac2145 and TEAD1*Ya5ac2013 Alu elements to reach the longevity.

2. Results
2.1. Population Analysis

Our study is the first, to our knowledge, to characterize the age-specific distribution of allele and genotype frequencies of the Alu polymorphic loci in genes associated with aging and longevity among healthy individuals from the Tatar ethnic group, aged between 18 and 113 years old (Table 1). We focused our research on genes encoding blood plasma enzymes (ACE, PLAT), components of extracellular matrix (COL13A1, LAMA2), key transcription factors and other functional genes implicated in the aging processes via regulation of homeostasis (HECW1, CDH4), growth and development (SEMA6A, TEAD1, CDH4), control of metabolism (HECW1), immune response (STK38L, PKHD1L1) and apoptosis (HECW1, STK38L). All studied loci were tested for compliance with the Hardy–Weinberg equilibrium. In a study involving practically healthy individuals, it is paramount to define the group with the genotype frequency distribution most closely resembling that in the general population without the selection influences. Many common diseases manifest in adulthood, between the ages of 45 and 59 years, most likely affected by the sedentary lifestyle and dietary habits prevalent in the modern world [36]. Another study established 45 years as typical age for the development of a number of common diseases [37]. Accordingly, the group of persons under 45 years was assigned for the population analysis as the most closely resembling the general population. We demonstrated the compliance with the Hardy–Weinberg equilibrium in the young group (18–44 years old): ACE*Ya5ACE ($P_{\text{HWE}} = 3.04 \times 10^{-1}$), HECW1*Ya5NBC182 ($P_{\text{HWE}} = 2.86 \times 10^{-1}$), SEMA6A*Yb8NBC597 ($P_{\text{HWE}} = 2.61 \times 10^{-1}$), CDH4*Yb8NBC516 ($P_{\text{HWE}} = 6.60 \times 10^{-2}$), STK38L*Ya5ac2145 ($P_{\text{HWE}} = 1.71 \times 10^{-1}$), PKHD1L1*Yb8AC702 ($P_{\text{HWE}} = 6.17 \times 10^{-1}$), TEAD1*Ya5ac2013 ($P_{\text{HWE}} = 3.12 \times 10^{-1}$), PLAT*TPA25 ($P_{\text{HWE}} = 5.10 \times 10^{-2}$), COL13A1*Ya5ac1986 ($P_{\text{HWE}} = 1.00$), LAMA2*Ya5-MLS19 ($P_{\text{HWE}} = 7.25 \times 10^{-1}$).

Table 1. Genotype frequencies (%) of the studied Alu polymorphic loci in age-divided groups.

| Genotype/Allele | Young (18–44 Years Old) | Middle-Aged (45–59 Years Old) | Elderly (60–74 Years Old) | Old Seniors (75–89 Years Old) | Long-Livers (90–113 Years Old) | $P_{\text{HWE}}$ |
|-----------------|------------------------|-------------------------------|--------------------------|-----------------------------|-----------------------------|-----------------|
| ACE Ya5ACE      |                        |                               |                          |                             |                             | 3.04 x 10^-1    |
| DD              | 28.95                  | 27.31                         | 29.11                    | 29.52                       | 25.34                       |
| ID              | 47.72                  | 54.63                         | 47.15                    | 45.93                       | 51.13                       |
| II              | 23.32                  | 18.06                         | 23.73                    | 24.55                       | 23.53                       |
| D               | 52.82                  | 54.63                         | 52.69                    | 52.48                       | 50.9                         |
| I               | 47.18                  | 45.37                         | 47.31                    | 47.52                       | 49.1                         |
| HECW1 Ya5NBC182 |                        |                               |                          |                             |                             | 2.86 x 10^-1    |
| DD              | 8.23                   | 16.79                         | 17.04                    | 12.30                       | 9.15                         |
| ID              | 46.75                  | 39.69                         | 42.59                    | 41.73                       | 46.41                       |
| II              | 45.02                  | 43.51                         | 40.37                    | 45.97                       | 44.44                       |
| D               | 31.60                  | 36.64                         | 38.33                    | 33.17                       | 32.35                       |
| I               | 68.40                  | 63.36                         | 61.67                    | 66.83                       | 67.65                       |
Table 1. Cont.

| Genotype/Allele | Young (18–44 Years Old) | Middle-Aged (45–59 Years Old) | Elderly (60–74 Years Old) | Old Seniors (75–89 Years Old) | Long-Livers (90–113 Years Old) | $P_{HWE} \ Y$ |
|-----------------|--------------------------|-------------------------------|---------------------------|-------------------------------|--------------------------------|------------------|
| SEMA6A Yb8NBC597 |                          |                               |                           |                               |                                | $2.61 \times 10^{-1}$ |
| DD              | 61.02                    | 66.91                         | 66.42                     | 62.43                         | 56.32                          |                  |
| ID              | 35.83                    | 28.06                         | 28.73                     | 31.98                         | 33.91                          |                  |
| II              | 3.15                     | 5.04                          | 4.85                      | 5.59                          | 9.77                           |                  |
| D               | 78.94                    | 80.94                         | 80.78                     | 78.42                         | 73.28                          |                  |
| I               | 21.06                    | 19.06                         | 19.22                     | 21.58                         | 26.72                          |                  |
| CDH4 Yb8NBC516  |                          |                               |                           |                               |                                | $6.60 \times 10^{-2}$ |
| DD              | 17.80                    | 25.25                         | 18.98                     | 14.44                         | 26.22                          |                  |
| ID              | 40.84                    | 41.41                         | 41.20                     | 44.61                         | 43.9                           |                  |
| II              | 41.36                    | 33.33                         | 39.81                     | 40.95                         | 29.88                          |                  |
| D               | 38.22                    | 45.96                         | 39.58                     | 36.75                         | 48.17                          |                  |
| I               | 61.78                    | 54.04                         | 60.42                     | 63.25                         | 51.83                          |                  |
| STK38L Ya5ac2145|                          |                               |                           |                               |                                | $1.71 \times 10^{-1}$ |
| DD              | 80.72                    | 82.55                         | 81.65                     | 79.96                         | 76.97                          |                  |
| ID              | 17.27                    | 15.44                         | 15.73                     | 18.34                         | 21.91                          |                  |
| II              | 2.01                     | 2.01                          | 2.62                      | 1.70                          | 1.12                           |                  |
| D               | 89.36                    | 90.27                         | 89.51                     | 89.13                         | 87.92                          |                  |
| I               | 10.64                    | 9.73                          | 10.49                     | 10.87                         | 12.08                          |                  |
| PKHD1L1 Yb8AC702|                          |                               |                           |                               |                                | $6.17 \times 10^{-1}$ |
| DD              | 22.35                    | 20.00                         | 19.21                     | 27.50                         | 30.2                           |                  |
| ID              | 51.76                    | 58.13                         | 60.93                     | 52.17                         | 49.5                           |                  |
| II              | 25.88                    | 21.88                         | 19.87                     | 20.33                         | 20.3                           |                  |
| D               | 48.24                    | 49.06                         | 49.67                     | 53.58                         | 54.95                          |                  |
| I               | 51.76                    | 50.94                         | 50.33                     | 46.42                         | 45.05                          |                  |
| TEAD1 Ya5ac2013 |                          |                               |                           |                               |                                | $3.12 \times 10^{-1}$ |
| DD              | 25.50                    | 28.38                         | 26.09                     | 27.45                         | 23.63                          |                  |
| ID              | 46.61                    | 42.57                         | 47.83                     | 44.72                         | 45.6                           |                  |
| II              | 27.89                    | 29.05                         | 26.09                     | 27.83                         | 30.77                          |                  |
| D               | 48.80                    | 49.66                         | 50.00                     | 49.81                         | 46.43                          |                  |
| I               | 51.20                    | 50.34                         | 50.00                     | 50.19                         | 53.57                          |                  |
| PLAT TPA25      |                          |                               |                           |                               |                                | $5.10 \times 10^{-2}$ |
| DD              | 31.70                    | 32.28                         | 29.05                     | 30.76                         | 33.33                          |                  |
| ID              | 44.12                    | 50.26                         | 43.24                     | 46.71                         | 40.38                          |                  |
| II              | 24.18                    | 17.46                         | 27.70                     | 22.53                         | 26.29                          |                  |
| D               | 53.76                    | 57.41                         | 50.68                     | 54.11                         | 53.52                          |                  |
| I               | 46.24                    | 42.59                         | 49.32                     | 45.89                         | 46.48                          |                  |
| COL13A1 Ya5ac1986|                         |                               |                           |                               |                                | $1.00$            |
| DD              | 5.63                     | 10.06                         | 7.77                      | 7.06                          | 9.42                           |                  |
| ID              | 36.62                    | 34.32                         | 42.07                     | 37.27                         | 32.74                          |                  |
| II              | 57.75                    | 55.62                         | 50.16                     | 55.67                         | 57.85                          |                  |
| D               | 23.94                    | 27.22                         | 28.80                     | 25.69                         | 25.78                          |                  |
| I               | 76.06                    | 72.78                         | 71.20                     | 74.31                         | 74.22                          |                  |
Table 1. Cont.

| Genotype/Allele | Young (18–44 Years Old) | Middle-Aged (45–59 Years Old) | Elderly (60–74 Years Old) | Old Seniors (75–89 Years Old) | Long-Livers (90–113 Years Old) | \( P_{HWE} \) |
|-----------------|--------------------------|-------------------------------|--------------------------|-------------------------------|-------------------------------|-------------------|
| **LAMA2 Ya5-MLS19** |                          |                               |                           |                               |                               | 7.25 × 10⁻¹ |
| DD              | 29.59                    | 36.51                         | 33.23                    | 37.21                         | 24.45                         |                  |
| ID              | 48.64                    | 41.80                         | 47.28                    | 44.87                         | 60.26                         |                  |
| II              | 21.77                    | 21.69                         | 19.49                    | 17.92                         | 15.28                         |                  |
| D               | 53.91                    | 57.41                         | 56.87                    | 59.65                         | 54.59                         |                  |
| I               | 46.09                    | 42.59                         | 43.13                    | 40.35                         | 45.41                         |                  |

Abbreviations: D—Alu deletion allele; I—Alu insertion allele; \( P_{HWE} \)—\( p \)-value of the Hardy–Weinberg equilibrium for the young group.

In the older age groups, among individuals without the chronic disease symptoms, selection may favor polymorphic variants that ensure more stable adaptive phenotypes. This was our main working hypothesis, which provided the basis for the further interrogation of individuals and, to a greater extent, polygenic predictors of longevity.

2.2. Age-Dependent Analysis of Individual Alu Polymorphic Loci

One of the most interesting research topics is establishing the possible selection of certain alleles at particular stages of ontogenesis, including the boundaries of the specified age periods. Therefore, we analyzed the age-specific dynamics of the genotype and allele frequencies of the Alu polymorphic loci in ten genes implicated in aging and longevity in our study group of individuals whose age ranged almost over a century—from 18 to 113 years. Pairwise comparison of age groups revealed differences in genotype and allele frequencies of Alu polymorphic loci in eight genes (Tables S1–S10).

For all the Alu polymorphic loci demonstrating these changes, the frequencies of alleles and genotypes begin to fluctuate starting from 60 years old. Statistically significant associations with age for the studied loci are shown in Table 2. In the elderly group we observed the higher frequency of the HECWI*DD genotype compared with the young group (17.04% vs. 8.23%, \( OR = 2.291, P = 4.00 \times 10^{-3} \)). The old group demonstrated a two-fold decrease in the CDH4*DD genotype frequency compared to the middle-aged group (14.44% vs. 25.25%, \( OR = 0.5, P = 9.00 \times 10^{-3} \)). People older than 90 years had a significant increase in LAMA2*ID genotype frequency in comparison with all the other age groups, with the strongest association found when comparing long-livers with the middle-aged individuals (60.26% vs. 41.8%, \( OR = 2.91, P_{\text{Bonf}} = 4.47 \times 10^{-3} \)) and the old group (60.26% vs. 44.87%, \( OR = 1.9, P = 5.51 \times 10^{-4}, P_{\text{Bonf}} = 1.54 \times 10^{-2} \)). The LAMA2*DD genotype frequency was decreased in the group of long-livers compared to the old group (24.45% vs. 37.21%, \( OR = 0.546, P = 5.00 \times 10^{-4}, P_{\text{Bonf}} = 1.45 \times 10^{-2} \)). Furthermore, the long-livers compared to the old seniors showed significant increase in the CDH4*DD genotype frequency (26.22% vs. 14.44%, \( OR = 2.106, 1.00 \times 10^{-3} \)), while the CDH4*I allele frequency was decreased (51.83% vs. 63.25%, \( OR = 0.475, P = 1.00 \times 10^{-3}, P_{\text{Bonf}} = 3.00 \times 10^{-2} \)). Comparing the long-livers with the elderly persons, we detected the decrease in the SEMA6A*D allele frequency (73.28% vs. 80.78%, \( OR = 0.471, P = 4.90 \times 10^{-2} \)) and even more pronounced decrease in the HECWI*DD genotype frequency (9.15% vs. 17.04%, \( OR = 0.490, P = 2.80 \times 10^{-2} \)). The frequency of the SEMA6A*I allele was more than 3-fold higher among long-livers than in the young group (9.77% vs. 3.15%, \( OR = 3.33, P = 6.00 \times 10^{-3} \)).
### Table 2. Associations of Alu polymorphic loci with age.

| Gene Alu Element | Genotype/Allele | Reference Group | OR (CI<sub>OR</sub>) | P     | Sex-Adjusted OR (CI<sub>OR</sub>) | Sex-Adjusted P |
|------------------|-----------------|-----------------|----------------------|-------|-----------------------------------|----------------|
|                  |                 |                 | Long-livers          |       |                                   |                |
|                  |                 |                 |                      |       |                                   |                |
| LAMA2 Ya5-MLS19  | DD              | Middle-aged     | 0.563 (0.369–0.859)  | 8.00  | 0.568 (0.358–0.903)               | 1.70 × 10<sup>-2</sup> |
|                  |                 | Elderly         | 0.651 (0.444–0.953)  | 2.70  | 0.648 (0.440–0.956)               | 2.90 × 10<sup>-2</sup> |
|                  |                 | Old seniors     | 0.546 (0.389–0.768)  | 5.00  | 0.554 (0.391–0.785)               | 1.00 × 10<sup>-3</sup> |
|                  | ID              | Young           | 1.633 (1.145–2.328)  | 7.00  | 1.491 (0.933–2.393)               | 9.50 × 10<sup>-2</sup> |
|                  |                 | Middle-aged     | 2.153 (1.449–3.201)  | 1.49  | 1.914 (1.237–2.959)               | 4.00 × 10<sup>-3</sup> |
|                  |                 | Elderly         | 1.724 (1.214–2.448)  | 2.00  | 1.726 (1.208–2.466)               | 3.00 × 10<sup>-3</sup> |
|                  |                 | Old seniors     | 1.900 (1.391–2.596)  | 5.51  | 1.815 (1.318–2.501)               | 2.66 × 10<sup>-4</sup> |
| CDH4 Yb8NBC516   | DD              | II              | 0.604 (0.389–0.939)  | 2.50  | 0.612 (0.345–1.083)               | 9.2 × 10<sup>-2</sup>  |
|                  |                 | Old seniors     | 0.614 (0.419–0.900)  | 1.20  | 0.670 (0.453–0.989)               | 4.40 × 10<sup>-2</sup>  |
|                  | I               | Young           | 0.609 (0.366–1.013)  | 5.60  | 0.680 (0.351–1.315)               | 2.50 × 10<sup>-1</sup>  |
|                  |                 | Old seniors     | 0.475 (0.308–0.733)  | 1.00  | 0.514 (0.330–0.800)               | 3.00 × 10<sup>-3</sup>  |
| SEMA6A Yb8NBC597 | DD              | II              | 0.652 (0.440–0.965)  | 3.30  | 0.640 (0.430–0.955)               | 2.90 × 10<sup>-2</sup>  |
|                  |                 | Old seniors     | 0.471 (0.223–0.996)  | 4.90  | 0.487 (0.228–1.042)               | 6.40 × 10<sup>-2</sup>  |
|                  | I               | Young           | 3.330 (1.404–7.899)  | 6.00  | 3.794 (1.257–11.449)              | 1.80 × 10<sup>-2</sup>  |
| PKHD1L1 Yb8AC702 | DD              | Middle-aged     | 1.730 (1.060–2.825)  | 2.80  | 2.022 (1.168–3.500)               | 1.20 × 10<sup>-2</sup>  |
|                  |                 | Elderly         | 1.820 (1.202–2.756)  | 5.00  | 1.780 (1.166–2.718)               | 8.00 × 10<sup>-3</sup>  |
|                  | ID              | Elderly         | 0.629 (0.439–0.901)  | 1.10  | 0.651 (0.451–0.940)               | 2.20 × 10<sup>-2</sup>  |
| PLAT TPA25       | II              | Middle-aged     | 1.686 (1.039–2.735)  | 3.40  | 1.634 (0.953–2.803)               | 7.40 × 10<sup>-2</sup>  |
|                  | ID              | Elderly         | 0.670 (0.468–0.960)  | 2.90  | 0.672 (0.466–0.968)               | 3.30 × 10<sup>-2</sup>  |
| HECW1 Ya5NBC182  | DD              | Elderly         | 0.490 (0.260–0.925)  | 2.80  | 0.473 (0.249–0.903)               | 2.30 × 10<sup>-2</sup>  |
|                  |                 | Old seniors     |                      |       |                                   |                |
| ACE Ya5ACE       | ID              | Middle-aged     | 0.706 (0.518–0.960)  | 2.70  | 0.706 (0.518–0.962)               | 2.70 × 10<sup>-2</sup>  |
| LAMA2 Ya5-MLS19  | DD              | Young           | 1.410 (1.048–1.897)  | 2.30  | 1.368 (0.994–1.882)               | 5.50 × 10<sup>-2</sup>  |
| CDH4 Yb8NBC516   | DD              | Middle-aged     | 0.500 (0.296–0.842)  | 9.00  | 0.479 (0.283–0.812)               | 6.00 × 10<sup>-3</sup>  |
| PKHD1L1 Yb8AC702 | DD              | Elderly         | 1.596 (1.138–2.237)  | 7.00  | 1.591 (1.134–2.231)               | 7.00 × 10<sup>-3</sup>  |
|                  | ID              | Elderly         | 0.699 (0.528–0.927)  | 1.30  | 0.708 (0.534–0.939)               | 1.70 × 10<sup>-2</sup>  |
| HECW1 Ya5NBC182  | DD              | Young           | 2.291 (1.300–4.038)  | 4.00  | 2.459 (1.306–4.631)               | 5.00 × 10<sup>-3</sup>  |
| PKHD1L1 Yb8AC702 | ID              | Young           | 1.453 (1.037–2.036)  | 3.00  | 1.380 (0.929–2.050)               | 1.10 × 10<sup>-1</sup>  |
| PLAT TPA25       | II              | Middle-aged     | 1.811 (1.151–2.851)  | 1.00  | 1.747 (1.095–2.787)               | 1.90 × 10<sup>-2</sup>  |

Abbreviations: D—Alu deletion allele; I—Alu insertion allele; OR—odds ratio; CI<sub>OR</sub>—95% confidence interval for OR; P—p-value; * indicates P-value that retains statistical significance after adjusting for multiple testing using Bonferroni correction (exact P<sub>adj</sub> are given in the text); associations with OR < 0.5 and OR > 2 are shown in bold.
Considering that sex has been shown to influence the lifespan, we additionally analyzed sex-specific associations between age and Alu polymorphisms in the studied genes (Table 2). The inclusion of sex as a predictor of attaining longevity in the logistic regression model led a two-fold increase in the chances of becoming a long-liver among individuals with the $PKHD1L1^{*DD}$ genotype (OR = 2.022, $P = 1.20 \times 10^{-2}$) and a mild decrease in the chances of reaching old age among individuals with the $CDH4^{*D}$ allele (OR = 0.479, $P = 6.00 \times 10^{-3}$). Associations identified for the other studied loci were not changed by the inclusion of sex.

Thus, the group of long-livers demonstrated the most significant changes in genotype and allele frequencies compared to all the other age groups. Moreover, the associations identified in the group of long-livers were the only ones that survived the multiple testing adjustment. Most notably, we established that among the long-livers the frequency of Alu insertion in the Yb8NBC516 locus of the $CDH4$ gene was reduced, and the number of $LAMA2^{*ID}$ genotype carriers was increased.

2.3. Polygenic Analysis of Longevity

Conducting a polygenic analysis required defining the age group that would be used as a control for individuals who had reached longevity. To define this group, we analyzed the results of a single-locus pairwise comparison of allele and genotype frequencies in various age periods and detected the differences, suggesting the possibility that genetic patterns conferring longevity may differ at distinct stages of ontogenesis. This may be due to complex networks of exo- and endogenous factors. During the lifespan, the human organism is affected by a variety of external influences, including those with deferred effects (for example, nutritional status during childhood, radiation, disease burden, psychosocial support, etc.). These factors interact with physiological, hormonal and epigenetic background changes during life. In such conditions, the hereditary background of a person can play different, and sometimes contradictory, combinations encoded by the gene set.

Using the APSampler (Allelic Pattern Sampler) algorithm, we tested all the possible options for our gene set comparing the group of long-livers with each age group, and with their combinations. As a result, we obtained the combinations of genotypes and alleles of the studied Alu polymorphic variants associated with longevity, with the control group established in four variants—18–74 years (1826 combinations), 18–89 years (5109 combinations), 60–89 years (2346 combinations) and 75–89 years (2401 combinations). The combinations with the highest statistical significance after the Bonferroni correction are presented in Table 3. All these polygenic patterns were associated with increased chances of attaining longevity (OR > 2). The Ya5-MLS19 locus of the $LAMA2$ gene is the key element that forms all the longevity-associated combinations. Its heterozygous variant in combination with the $Yb8NBC516^{*D}$ allele of the $CDH4$ gene promotes longevity when compared with all the age groups selected as controls. At the same time, the combination of the $LAMA2^{*ID}$, $CDH4^{*D}$ and $SEMA6A^{*I}$ was significantly more frequent (22.22% vs. 8.37%, OR = 3.13, $P = 1.80 \times 10^{-5}$, $P_{\text{Bonf}} = 2.00 \times 10^{-2}$). The pattern combining the $CDH4^{*DD}$ genotype with $LAMA2^{*D}$ and $ACE^{*I}$ alleles was more common among long-livers than among persons of the old group (75–89 years) (19.08% vs. 6.02%, OR = 3.68, $P = 7.76 \times 10^{-6}$, $P_{\text{Bonf}} = 1.90 \times 10^{-2}$).

For the elements of the identified combinations, we additionally calculated the individual ORs to compare their individual effects and the effects in combinations (Table S11). We found that the average individual OR values were around 1.5. We established that the maximum ORs obtained for the $CDH4^{*DD}$ (2.11) and $LAMA2^{*ID}$ (1.84) loci were still lower than in combinations with the other markers. Thus, using the APSampler algorithm, we successfully identified the combinations of the studied loci significantly associated with longevity.
Table 3. Allelic/genotype combinations most significantly associated with longevity according to APSampler analysis.

| Combinations | Compared Age Periods | P     | P_{Bonf} | OR   | CI_{OR} |
|--------------|----------------------|-------|----------|------|---------|
|              | 18–74                | 18–89 | 60–89     | 75–89| 90–113  |
| LAMA2 Ya5-MLS19*ID + CDH4 Yb8NBC516*DD + HECW1 Ya5NBC182*D | 3.77  | 15.22  | 1.70 \times 10^{-6} | 9.00 \times 10^{-3} | 4.58 | 2.56–8.21 |
| LAMA2 Ya5-MLS19*D + CDH4 Yb8NBC516*DD + HECW1 Ya5NBC182*D | 4.76  | 17.39  | 1.09 \times 10^{-5} | 2.60 \times 10^{-2} | 4.21 | 2.23–7.96 |
| LAMA2 Ya5-MLS19*D + CDH4 Yb8NBC516*DD + ACE Ya5ACE*I | 6.02  | 19.08  | 7.76 \times 10^{-6} | 1.90 \times 10^{-2} | 3.68 | 2.09–6.49 |
| LAMA2 Ya5-MLS19*ID + CDH4 Yb8NBC516*DD + SEMA6A Yb8NBC597*I | 8.37  | 22.22  | 1.08 \times 10^{-5} | 2.00 \times 10^{-2} | 3.13 | 1.90–5.16 |
| LAMA2 Ya5-MLS19*ID + CDH4 Yb8NBC516*D | 28.12 | 46.58  | 3.76 \times 10^{-6} | 1.90 \times 10^{-2} | 2.23 | 1.59–3.13 |
| LAMA2 Ya5-MLS19*ID + HECW1 Ya5NBC182*I | 40.75 | 60.27  | 8.29 \times 10^{-6} | 1.90 \times 10^{-2} | 2.21 | 1.55–3.15 |

Abbreviations: *—the data for the compared age groups are presented as the frequencies of allelic/genotype combinations (%); D—Alu deletion allele; I—Alu insertion allele; the asterisk is used to separate the name of polymorphism and allele or genotype; P—significance level estimated using Fisher’s exact test; P_{Bonf}—significance level corrected for multiple testing using Bonferroni correction; OR—odds ratio; CI_{OR}—95% confidence interval for OR.

3. Discussion

In our study, we explored the polygenic associations between a complex of Alu polymorphic loci and longevity in the ethnic group of Tatars. The most informative polygenic predictors of longevity included, first of all, Alu deletions in the LAMA2, CDH4 and HECW1 genes, as well as Alu insertions in the SEMA6A and ACE genes. Notably, all six most significant patterns of longevity included the Ya5-MLS19 locus of the LAMA2 gene, and five the Yb8NBC516 locus of the CDH4 gene. Thus, the genes most prominently associated with human longevity according to our results encode proteins involved in the maintenance of the extracellular matrix and cell adhesion.

Adhesive glycoproteins of the extracellular matrix are represented mainly by large molecules of laminins. They constitute the stroma of the basement membrane and, by binding to cells through affinity receptors, are involved in the organization, attachment and migration of cells in tissues [38]. They also affect the proliferation, differentiation and function of cells connected to basement membranes [39]. Laminins are heterotrimers of α, β and γ chains, each of which have several variants. Combinations of these chains in a polypeptide molecule form at least 15 isoforms of laminin [38]. The α-2 chain, which is one of the subunits of laminin-2 (merosin) and laminin-4 (s-merosin), is encoded by the gene LAMA2. The LAMA2 gene is mainly expressed in basement membranes of striated muscle, Schwann cells and some other tissues [38]. A change in the amino acid composition can cause a violation of the protein structure, which is manifested in the inability to polymerize and form full-fledged basement membranes of myofibrils in muscle tissue [40]. More than 300 mutations in the LAMA2 gene have been identified so far in patients with congenital myotonic dystrophy type 1 [41]. Laminin-2 is also widely researched in the study of common human diseases at late stages of ontogenesis. A decrease in LAMA2 gene expression level is observed in some types of cancer and is a predictor of poor survival of cancer patients [15]. Mutations in the LAMA2 gene also cause various damage to brain structures and changes in the Substantia alba [42], leading to impaired myelination of neurons [43]. These changes are associated with age-related neurodegenerative pathologies. The anti-amyloidogenic
role of laminin has been discovered, which is of interest for the development of approaches
to the treatment of Alzheimer’s disease [44]. Laminin-2, derived from pericytes, mediates
stimulation of oligodendrocyte differentiation after demyelination [45]. The important
role of laminin-2 in the organization and maintenance of homeostasis in neurons is also
emphasized in the engineering of peripheral nerve repair [46]. Thus, the role of laminins
in aging and longevity is studied mainly within the framework of the searching for a
connection with age-associated neurodegenerative pathologies. However, for example,
an analysis of the laminin levels in the blood serum and cerebrospinal fluid showed no
relationship between the concentration of this protein and Alzheimer’s disease and its
increase with age [47]. However, a later experiment demonstrated the decrease in the levels
of laminin in vascular basement membranes in aged mice relative to young mice [48]. In
general, it is noted that the different levels of laminin activity in the studies of aging are
explained by tissue specificity [49]. Here, we established a correlation of the heterozygous
LAMA2*Ya5-MLS19 genotype with longevity, that is, the presence of one allele containing
the Alu element contributed to an increase in lifespan and may indicate an overdominant
effect on the highly adaptive phenotype. In two identified patterns, the presence of the
LAMA2*D allele provided the long-livers with an advantage over old individuals aged
under 90 years. Bearing in mind the inhibitory effect of Alu insertions on the expression of
genes containing them [50], it is likely that a moderate and elevated level of laminin-2 is
associated with longevity.

Cadherins also belong to the proteins that perform the function of intercellular adhe-
sion and thus ensure the stability of a multicellular organism. Cadherins are cell membrane
glycoproteins that carry out calcium-dependent homotypic adhesion during early em-
byronic development. Cadherins play a key morphogenetic role in tissue development,
providing cell–cell interactions necessary for sorting and migration of cells, as well as forma-
tion and maintenance of tissue boundaries [51]. In nervous tissue, cadherins are critical for
the formation of Nervorum capitalium and the neuronal networks, including the neuronal
recognition of effector cells [52]. In a review dedicated to the structure and functioning of
the extracellular matrix of the glycocalyx and the blood–brain barrier, particular importance
is given to cadherin as an agent that provides adhesion at the pericyte–endothelium inter-
face [49]. More than one hundred members of the cadherin family have been identified, one
of which, R-cadherin (cadherin 4, type 1), is encoded by the CDH4 gene. The R-cadherin
gene has been studied mainly in relation to malignancies, and persistent associations of
the risk of cancer have been reported with decreased CDH4 gene expression [16,17]. In
contrast to healthy cells with a demethylated promoter, 57–95% of cancer cells have a
methylated CDH4 promoter [18]. An increase in CDH4 gene expression was revealed in a
model of chronic sustained hypoxia in comparison with the control [53]. According to the
GWAS results, aging among a Framingham cohort was associated with SNPs rs1970546
and rs2024714 located in CDH4 genes [18,22]. Another GWAS also revealed the associations
of this gene with age-related changes and longevity [33]. Moreover, an analysis of the set of
longevity-associated loci demonstrated the enrichment of genes that control the processes
of cell adhesion and cell–cell interactions [33]. This suggests the active involvement of
genes associated with cancer-related processes (in this case, protection against cancer) in
the formation of a stable highly adaptive phenotype contributing to longevity. Regarding
the Alu polymorphism of the CDH4 gene, the presence of the Yb8NBC516*D allele predomi-
nantly in the homozygous state in combinations associated with longevity may indicate
an important role of this gene activity in protecting against cancer.

The combination most significantly associated with longevity included, in addition
to the adhesion molecule genes, the Alu deletion allele of the HECW1 gene. The HECW1
gene encodes the E3 ubiquitin ligase, which contains the C2 and WW domains and is
involved in the ubiquitin-dependent degradation of proteins in proteasomes. This protein
is abundant in neuronal tissues such as brain and spinal cord [54]. Thus, due to its partici-
pation in protein homeostasis, HECW1 is a key element in the normal and pathological
development of nervous system [55]. The HECW1 gene product controls the cell cycle
through the enhancement of the transcriptional and pro-apoptotic activity of p53 [56]. The HECW1 protein also ubiquitinates the mutant form of the superoxide dismutase (SOD1) enzyme in people with hereditary amyotrophic lateral sclerosis, binds to amyloid-sensitive epithelial sodium channels and possibly participates in the regulation of their activity. Another target of HECW1 is the DVL1 gene, a member of the Wnt pathway, which controls carcinogenesis and embryonic development [54]. Thus, HECW1 is involved in the regulation of morphogenesis, apoptosis and response to oxidative stress. The HECW1 gene has been linked to oncological disorders [56]. A significant increase in HECW1 expression was shown in pathological tissues in non-small cell lung cancer [19]. However, HECW1 was significantly down-regulated in clear cell renal cell carcinoma [20]. In total, the protein degradation controlled by the E3 ubiquitin ligases is surmised to play a fundamental role in the self-renewal, maintenance and differentiation of cancer stem cells [57]. This is essential for the development of a pathological senile phenotype. Moreover, it is interesting that there is an inverse correlation between oncological and neurodegenerative diseases, which can be explained by the multiple roles of the p53 protein signaling network. HECW1 might have opposite effects in tumorigenesis and the development of neuronal diseases by enhancing p53-mediated apoptotic cell death [26]. Thus, in old age, the same triggers can both provoke the diseases and provide resistance to them. The polygenic analysis of associations can assess the accumulation of small independent subthreshold effects of alleles. As a result, complex markers can be qualitatively different from the individual effects of each allele [58]. The Alu insertion allele of the HECW1 gene can therefore have a different effect on resistance to age-related diseases and the attainment of longevity status. This is demonstrated by our results: the combinations associated with longevity include not only HECW1*D, but also the allele containing the Alu insertion.

The Alu insertion allele of the SEMA6A gene is another component that modulates the effects of combinations associated with longevity. The protein product of the SEMA6A gene is the signaling membrane-bound semaphorin-6. During ontogenesis, the transcriptional activity of the SEMA6A gene may change [59]. This may suggest the implication of the SEMA6A gene in the development of age-associated phenotypes. Semaphorin-6 is shown to be involved in the structural and functional organization of the nervous system, primarily in axonal guidance [60]. Knockout of the SEMA6A gene led to pathologies of the nervous system; in addition, semaphorin-6 plays an important role as a receptor of thalamocortical neurons [61]. Moreover, the SEMA6A gene is expressed in certain tumor cells and promotes their growth independent of cell adhesion [62]. SEMA6-induced signals are involved in the regulation of apoptosis, particularly in cancer cells [21]. Various mutations of the SEMA6A gene were associated with a range of diseases. For example, rs26595 is associated with autoimmune Wegener’s granulomatosis [63], and rs154576 is associated with a higher risk of Trichophyton tonsurans infection [64]. In addition, impaired expression of the SEMA6A gene led to a decrease in sensitivity to the exotoxin TcsL [65], which reveals the participation of semaphorin-6 in resistance to infectious agents. Thus, semaphorin-6 plays an important role in the development of the nervous, cardiovascular and immune systems [66], and can potentially be involved in the pathogenesis of the diseases affecting these systems that mostly develop with age. Semaphorin-6 is essential, particularly, for the development of blood vessels and adult angiogenesis [67]. In type 2 diabetes, inhibition of miR-27a/b, which targets the angiogenesis repressor SEMA6A, promotes better healing of diabetic wounds [27]. The findings on the participation of repressed SEMA6A in regeneration processes are in accordance with our results demonstrating that the presence of the Alu element in the gene that suppresses its activity is associated with longevity.

Among the combinations most significantly associated with longevity according to our results, the one that includes the Y65ACE*I allele of the ACE gene encoding angiotensin-converting enzyme occurs three times more frequently in the group of long-livers than in the group of old people (75–89 years). The ACE*I allele is associated with a significantly lower level of the vasoconstricting angiotensin II in the blood and, accordingly, with resistance to the development of cardiovascular diseases [23,24]. Previously, this allele has
already shown an association with longevity in some human populations [34,35]. However, according to the results of a meta-analysis, the longevity phenotype was associated with the ACE*D allele [31]. The authors call this result paradoxical (the genotype and allele associated with a high risk of cardiovascular diseases become more common with age), but they link these findings to the observation that an increase in the angiotensin-converting enzyme level prevents the onset of Alzheimer’s disease [31]. In addition, ACE being an amyloid-degrading enzyme, it can decrease amyloid toxicity [25]. The most recent findings regarding the Alu polymorphic locus in the ACE gene are related to the interaction of the human and viral genomes, and consider human longevity as a phenotype resistant to infectious agents. The ACE*I allele has shown protective effects against COVID-19 disease and its severe complications [13]. Alu insertions in genes have been demonstrated to increase host resistance to viral infection: double-stranded RNAs transcribed from Alu elements activate antiviral innate immune signaling pathways in mitochondria through MDA5—a viral dsRNA sensor [68]. In total, the favorable role of low ACE activity and the Alu insertion in the ACE gene are more pronounced in physiological backgrounds specific to the late stages of ontogenesis.

Our study has several limitations. We focused on the Alu insertion and deletions in ten genes that were chosen based on their potential significance for aging and longevity. Alu elements located elsewhere in the human genome could further elucidate the mechanisms of aging. Additional research of the biological background and functional studies are needed to explain our results. Another limitation of the study concerns the relatively small size of the study group of long-livers, although it should be noted that longevity is the exceptional survival phenotype and therefore is accompanied by certain challenges in finding these people, especially healthy ones, among the population. Further studies with larger and more diverse ethnic populations are required to validate our results. Our study was restricted to the population of Tatars from the Volga-Ural region of Russia, which, in addition to limiting the ability to generalize the results for a broader population, at the same time acts as one of the strengths of our study increasing the ethnic homogeneity of the total sample. That allows us to avoid the problems related to the possible population heterogeneity. To minimize the influence of the external environmental factors that could significantly affect the lifespan and the quality of life, the study sample was comprised of the indigenous population of the Volga-Ural region of Russia, born and permanently residing in the Republic of Bashkortostan. Polygenic analysis was performed using the APSampler algorithm, which does not allow the adjustment for sex, and therefore associations observed for the combinations of the genotypes/alleles of the studied loci could be partly attributed to sex differences in the aging processes. However, this program has proven to be a powerful tool for identifying complex genetic predictors [69].

According to the results of our analysis of genes comprising the polygenic predictors of longevity, the proteins maintaining the integrity and composition of complex structures of the organism are especially important for preserving the homeostasis and success of the later stages of ontogenesis. Moreover, all these elements are involved in the structural and functional organization of the nervous system, both under normal conditions and at exposure to endo- and exogenous destabilizing factors (viruses, stress, inflammaging). Age-dependent DNA destabilization leads to the activation of retrotransposons, including Alu, and initiates the neurodegenerative processes [70]. This is very important, because in addition to the increasing with age risk of cancer and cardiovascular disorders, the conditions of modern society provoke the development of neuropsychiatric disorders. The necessity to process the rapidly growing volume of digital data affects the functioning of the nervous system, with its evolutionarily conserved mechanisms for processing information. Alu insertions can provide a molecular background for increasing plasticity and adaptation to certain extreme conditions for the nervous system. For other structures of an organism, stability can be important and advantageous at all stages of ontogenesis, and therefore selection can favor Alu deletions. By affecting gene activity, Alu deletions and
Alu insertions together can modulate the effects that influence the development of a highly adaptive phenotype of longevity.

4. Materials and Methods

4.1. Study Group

Our study was conducted according to the ethical principles for biomedical research involving human subjects outlined in the Declaration of Helsinki of the World Medical Association in 2013, and with the approval of the Bioethics Committee of the Institute of Biochemistry and Genetics of Ufa Federal Research Center of Russian Academy of Sciences (protocol No. 1 dated 28 October 2007). A total of 2054 individuals aged 18 to 113 were randomly selected among the residents of the Republic of Bashkortostan, located in Volga-Ural region of Russia. The groups of elderly people were collected in the City Boarding Homes for the Elderly and Disabled of Ufa and Oktyabrsky, the Ufa War Veterans Hospital and the Central District Hospitals of the Republic of Bashkortostan. The groups of young and middle-aged individuals were selected among those who attended the Ufa City Hospitals and the Central District Hospitals of the Republic of Bashkortostan for regular medical checkup. All volunteers signed the informed consent to participation in the study. DNA samples used in the study were anonymized. To avoid potential risk of distorting results arising from population stratification our sample was ethnically homogenous. All study participants identified themselves and their ancestors in three generations as ethnic Tatars. The total sample was divided into age groups of the young (18–44 years old), middle-aged (45–59 years old), elderly (60–74 years old), old seniors (75–89 years old) and long-livers (over 90 years old) according with the WHO recommendations [71]. The characteristics of the differentiated age groups are presented in Table 4. Total group included healthy individuals without disorders of cardiovascular and nervous systems. Among elderly and old people, as well as long-livers, for whom age-related functional changes in the cardiovascular system, with rare exceptions, are practically the norm, a history of atherosclerosis, ischemic heart disease and cerebral sclerosis was allowed. We established a special criterion of vitality for the long-livers, which we defined as the ability to take care of themselves, maintain physical activity and the preservation of lucidity.

Table 4. Characteristic of studied group.

| Age Group     | Age Range, Years Old | Sample Size, n | Mean Age ± SD, Years Old | Male/Female, n (%) |
|---------------|----------------------|----------------|--------------------------|--------------------|
| Young         | 18–44                | 542            | 31.92 ± 7.82             | 390/152 (71.96/28.04) |
| Middle-aged   | 45–59                | 261            | 50.87 ± 4.42             | 152/109 (58.04/41.76) |
| Elderly       | 60–74                | 321            | 68.39 ± 3.93             | 107/214 (33.33/66.67) |
| Old seniors   | 75–89                | 693            | 80.48 ± 3.74             | 287/406 (41.41/58.59) |
| Long-livers   | 90–113               | 237            | 93.16 ± 2.97             | 39/198 (16.46/83.54)  |
| Total         | 18–113               | 2054           | 63.48 ± 22.65            | 975/1079 (47.47/52.53) |

4.2. DNA Collection

The samples of 8 µL peripheral venous blood were collected using a vacuum system and stored at −4 °C. DNA was isolated from blood using a standard phenol-chloroform extraction method. DNA samples were stored in 96% ethanol. For PCR procedures, aliquots of DNA samples were dried, dissolved in deionized water and their concentration was equalized (50 ng/µL). The DNA quality was assessed by electrophoresis in 0.8% agarose gel and quantified by ultraviolet absorbance spectrophotometric analysis. DNA aliquot solutions were stored at −20 °C.
4.3. Genotyping

Information about Alu polymorphic regions of studied genes was collected from genomic databases TranspoGene, RepeatMasker and dbRIP. Localization of insertions within genes, their genomic context and flanking sequence data were obtained using the UCSC genomic browser (http://genome.ucsc.edu, accessed on 15 April 2019). Oligonucleotide primers were designed using the Primer-BLAST software (https://blast.ncbi.nlm.nih.gov/Blast.cgi, accessed on 25 April 2019). The insertion or deletion of the Alu element in the studied locus was determined by PCR procedure followed by separation of fragments of the amplified DNA regions using electrophoresis in 2% agarose gel. The list of Alu polymorphic loci and conditions of PCR procedure are presented in Table 5.

Table 5. Nomenclature, genetic localization, amplification conditions and length of the amplified alleles for the studied Alu polymorphic loci.

| Alu Element | Gene, Chromosome Location | Primers | Annealing Temperature (°C) | Alleles (Fragment Length, bp) |
|-------------|---------------------------|---------|---------------------------|-------------------------------|
| Ya5ACE      | ACE 17q23.3               | F 5’-ctg gag acc act ccc atc ctt tct-3’  R 5’-gat gtg gcc atc atc ttc gtc aga t-3’ | 68                           | I (490) D (190)               |
| Ya5NBC182   | HECWI 7p13                | F 5’-gaa gga cta tgt tgt tgt agc agc-3’  R 5’-aac cca gtc gaa aca gaa gat g-3’ | 64                           | I (563) D (287)               |
| Yb8NBC597   | SEMA6A 5q23.1             | F 5’-tga ggt gtt gca gac gat gt-3’  R 5’-gcg tag ctt tag aga ata ccc-3’ | 63                           | I (429) D (108)               |
| Yb8NBC516   | CDH4 20q13.33             | F 5’-ggg ctc agg gat act atg ctc-3’  R 5’-gcc tag gcc tac cac tca ga-3’ | 60                           | I (445) D (124)               |
| Ya5ac2145   | STK38L 12p11.23           | F 5’-tct tct ctt ctt gat ctc gac ccc-3’  R 5’-tgc ctt tag gaa gct aca gat tta-3’ | 60                           | I (465) D (135)               |
| Yb8AC702    | PKHD1L1 8q23.2            | F 5’-ttg gaa ata agc cca aca at-3’  R 5’-ggg tag cca gct ttt tca ctc tct-3’ | 60 (7 cycles) 60 (22 cycles) | I (482) D (161)               |
| Ya5ac2013   | TEAD1 11p15.2             | F 5’-ctg att ctc ctc ctc ctc ctc ctc-3’  R 5’-gta gta gta gta gta gta gta-3’ | 60                           | I (489) D (212)               |
| TPA25       | PLAT 8q11.21              | F 5’-gta cta ggt ctc gcc ctc ctc ctc ctc-3’  R 5’-gcg gtc gtc gtc gtc gtc gtc gtc-3’ | 60                           | I (518) D (217)               |
| Ya5ac1986   | COL13A1 10q22.1           | F 5’-ctg gat ctc ctc ctc ctc ctc ctc-3’  R 5’-ttt gta gta gta gta gta gta gta-3’ | 60                           | I (431) D (134)               |
| Ya5-MLS19   | LAMA2 6q22.33             | F 5’-ctg agt ggg ctc ctc ctc ctc ctc ctc-3’  R 5’-ggg gga gga gga gga gga gga gga gga gga-3’ | 63 (7 cycles) 60 (22 cycles) | I (401) D (106)               |

Abbreviations: F—forward primer; R—reverse primer; bp—base pair; D—Alu deletion allele; I—Alu insertion allele.

4.4. Statistical Analysis

Statistical processing of genotyping results was carried out using the software GenePop (v.3.1, Montpellier, France), APSampler (v.3.6.1, San Diego, CA, USA) and the statistical software package SPSS (v.21.0, Chicago, IL, USA). The match of the observed distribution of genotype frequencies to the theoretically expected Hardy–Weinberg equilibrium was assessed by the chi-square test. Genotype and allele frequencies in age groups were compared in pairs using Fisher’s exact two-tailed test. The estimation of associations between the studied Alu polymorphic loci and age was performed using logistic regression analysis. The search for combinations of the studied Alu polymorphic markers associated with longevity was carried out using the APSampler; the software uses the Markov chain Monte Carlo method based on Bayesian approaches [58] and is available at http://apsampler.sourceforge.net/, accessed on 7 May 2021. Taking into account the multiple comparisons, the Bonferroni correction was used, while the differences were considered significant at \( P_{\text{Bonf}} < 0.05. \)
5. Conclusions

For the first time, we analyzed the dynamics of the allele and genotype frequencies of the Alu polymorphic loci in genes significant for longevity among healthy people aged between 18 and 113 years old in the ethnically homogeneous population of the Volga-Ural region of Russia. Significant changes in allele and genotype frequencies were observed between the long-livers and other groups. The key elements of polygenic predictors of longevity were the Alu deletion alleles of the \textit{CDH4} and \textit{LAMA2} genes, which control the physiological functioning of the system maintaining cell interactions. The presence of the Alu deletion and Alu insertion alleles of the \textit{HECW1} gene in combinations associated with longevity may be mediated by dual effects resulting in age-related diseases. The modulating components of polygenic models of longevity are Alu insertion alleles of the \textit{SEMA6A} and \textit{ACE} genes involved in resistance to infectious agents and associated with tolerance to multifactorial age-related diseases. All five elements of the identified polygenic predictors of longevity (Alu polymorphic loci of \textit{CDH4}, \textit{LAMA2}, \textit{HECW1}, \textit{SEMA6A} and \textit{ACE} genes) are involved in the development and stability of structures of the nervous system, and in general in the maintaining of integration systems of the body. It points to the significance of the identified polygenic patterns for longevity.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ijms232113492/s1.

Author Contributions: Conceptualization, V.V.E. and D.D.K.; methodology, D.D.K. and T.R.N.; software, T.R.N.; validation, I.A.T. and D.D.K.; formal analysis, V.V.E., D.D.K. and T.R.N.; investigation, D.D.K., I.A.T. and V.V.E.; data curation, V.V.E.; writing—original draft preparation, V.V.E.; writing—review and editing, Y.R.T., G.F.K., T.R.N. and V.V.E.; visualization, V.V.E.; project administration, V.V.E. and G.F.K.; funding acquisition, Y.R.T. All authors have read and agreed to the published version of the manuscript.

Funding: The research was supported by the megarant of the Government of Russian Federation No. 075-15-2021-595 and NIR No. 122041400169-2; biological material (DNA) for studies was obtained from the Collection of Human Biological Materials of the Institute of Biochemistry and Genetics, Ufa Federal Research Center, Russian Academy of Sciences, supported by the Bioresource Collections Program of the Russian Federal Agency for Scientific Organizations; the study was carried out using the equipment of the Biomik Center for collective use and the UNU Kodink (Institute of Biochemistry and Genetics, Ufa Federal Research Center, Russian Academy of Sciences).

Institutional Review Board Statement: The study was approved by the Bioethics Committee of the Institute of Biochemistry and Genetics of the Ufa Federal Research Center of Russian Academy of Sciences (protocol No. 1 dated 28 October 2007) and was conducted according to the Declaration of Helsinki.

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: Data will be available upon request.

Acknowledgments: We thank all the participants and their families for their contribution in the study. We acknowledge the medical personnel of the City Boarding Homes for the Elderly and Disabled of Ufa and Oktyabrsky, the Ufa War Veterans Hospital, the Ufa City Hospitals and the Central District Hospitals of the Republic of Bashkortostan.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Sebastiani, P.; Perls, T.T. The genetics of extreme longevity: Lessons from the new England centenarian study. \textit{Front. Genet.} \textbf{2012}, \textit{3}, 1–7. [CrossRef] [PubMed]

2. Zeng, Y.I.; Nie, C.; Min, J.; Liu, X.; Li, M.; Chen, H.; Xu, H.; Wang, M.; Ni, T.; Li, Y.; et al. Novel loci and pathways significantly associated with longevity. \textit{Sci. Rep.} \textbf{2016}, \textit{6}, 1–13. [CrossRef]

3. Pilling, L.C.; Kuo, C.L.; Sicinski, K.; Tamagoukaita, J.; Kuchel, G.A.; Harries, L.W.; Herd, P.; Wallace, R.; Ferrucci, L.; Melzer, D. Human longevity: 25 genetic loci associated in 389,166 UK biobank participants. \textit{Aging} \textbf{2017}, \textit{9}, 2504–2520. [CrossRef] [PubMed]
4. Deelen, J.; Evans, D.S.; Arking, D.E.; Tesi, N.; Nygaard, M.; Liu, X.; Wojczynski, M.K.; Biggs, M.L.; van der Spek, A.; Atzmon, G.; et al. A meta-analysis of genome-wide association studies identifies multiple longevity genes. **Nat. Commun.** 2019, **10**, 1–14. [CrossRef]

5. Gladyshev, V.N. The origin of aging-imperfectness-drive non-random damage defines the aging process and control of lifespan. **Trends Genet.** 2013, **29**, 506–512. [CrossRef]

6. Kim, S.; Cho, C.S.; Han, K.; Lee, J. Structural Variation of Alu Element and Human Disease. **Genom. Inf.** 2016, **14**, 70–77. [CrossRef]

7. Hueso, M.; Cruzado, J.M.; Torras, J.; Navarro, E. ALUminating the Path of Atherosclerosis Progression: Chaos Theory Suggests a Role for Alu Repeats in the Development of Altherosclerotic Vascular Disease. **Int. J. Mol. Sci.** 2018, **19**, 1734. [CrossRef]

8. Kubiak, M.R.; Makalowska, I. Protein-Coding Genes’ Retrocopies and Their Functions. **Viruses** 2017, **9**, 80. [CrossRef]

9. Todd, C.D.; Deniz, Ö.; Taylor, D.; Branco, M.R. Functional evaluation of transposable elements as enhancers in mouse embryonic and trophoblast stem cells. **Elife** 2018, **8**, e44344. [CrossRef]

10. Ule, J. Alu elements: At the crossroads between disease and evolution. **Biochem. Soc. Trans.** 2013, **41**, 1532–1535. [CrossRef]

11. Klawitter, S.; Fuchs, N.V.; Upton, K.R.; Munoz-Lopez, M.; Shukla, R.; Wang, J.; Garcia-Canadas, M.; Lopez-Ruiz, C.; Gerhardt, D.J.; Sebe, A.; et al. Reprogramming triggers endogenous L1 and Alu retrotransposition in human induced pluripotent stem cells. **Nat. Commun.** 2016, **7**, 1–14. [CrossRef] [PubMed]

12. Fedoroff, N.V. Transposable elements, epigenetics, and genome evolution. **Science** 2012, 338, 758–767. [CrossRef] [PubMed]

13. Li, M.; Schifanella, L.; Larsen, P.A. Alu retrotransposons and COVID-19 susceptibility and morbidity. **Hum. Genom.** 2021, **15**, 2–11. [CrossRef] [PubMed]

14. Maxwell, P.H. What might retrotransposons teach us about aging? **Curr. Genet.** 2016, **62**, 277–282. [CrossRef] [PubMed]

15. Lin, T.; Lin, Z.; Mai, P.; Zhang, E.; Peng, L. Identification of prognostic biomarkers associated with the occurrence of portal vein tumor thrombus in hepatocellular carcinoma. **Aging** 2021, **13**, 11786–11807. [CrossRef]

16. Zhou, X.; Huang, H.; Cui, W.; Wang, Y.; Luo, W.; Matskova, L.; Zhou, X. Expression and Prognostic Significance of Cadherin 4 (CDH4) in Renal Cell Carcinoma. **Med. Sci. Monit.** 2020, **26**, e922836. [CrossRef]

17. Xu, M.; Liu, C.; Pu, L.; Lai, J.; Li, J.; Ning, Q.; Liu, X.; Deng, S. Systemic analysis of the expression levels and prognosis of breast cancer-related cadherins. **Exp. Biol. Med.** 2021, **246**, 1706–1720. [CrossRef]

18. Lu, C.; Ning, G.; Si, P.; Zhang, C.; Liu, W.; Ge, W.; Cui, K.; Zhang, R.; Ge, S. E3 ubiquitin ligase HECW1 promotes the metastasis of non-small cell lung cancer cells through mediating the ubiquitination of Smad4. **Biochem. Cell Biol.** 2021, **99**, 675–681. [CrossRef]

19. Wang, C.; Dong, K.; Wang, Y.; Peng, G.; Song, X.; Yu, Y.; Cui, X. Integrating HECW1 expression into the clinical indicators exhibits high accuracy in assessing the prognosis of patients with clear cell renal cell carcinoma. **BMC Cancer** 2021, **21**, 890. [CrossRef]

20. Shen, C.Y.; Chang, Y.C.; Chen, L.H.; Lin, W.C.; Lee, Y.H.; Yeh, S.T.; Chen, H.K.; Fang, W.; Hsu, C.P.; Lee, J.M.; et al. The extracellular SEMA domain attenuates intracellular apoptotic signaling of semaphorin 6A in lung cancer cells. **Oncogenesis** 2018, **7**, 95. [CrossRef]

21. Seshadri, S.; DeStefano, A.L.; Au, R.; Massaro, J.M.; Beiser, A.S.; Kelly-Hayes, M.; Kase, C.S.; D’Agostino, R.B.; DeCarli, C.; Atwood, L.D.; et al. Genetic correlates of brain aging on MRI and cognitive test measures: A genome-wide association and linkage analysis in the Framingham Study. **BMJ Med. Genet.** 2007, **8**, S15. [PubMed]

22. Wei, L.K.; Au, A.; Menon, S.; Griffiths, L.R.; Kooi, C.W.; Irene, L.; Zhao, J.; Lee, C.; Avdonina, M.A.; Hassan, M.R.A.; et al. Polymorphisms of MTHFR, eNOS, ACE, AGT, ApoE, PON1, PDE4D, and Ischemic Stroke: Meta-Analysis. **J. Stroke Cereb. Dis.** 2017, **26**, 2482–2493. [CrossRef] [PubMed]

23. Amara, A.; Mrad, M.; Sayeh, A.; Lahideb, D.; Layouni, S.; Haggui, A.; Fekih-Mrissa, N.; Haouala, H.; Nsiri, B. The effect of ACE I/D polymorphisms alone and with concomitant risk factors on coronary artery disease. **Clin. Appl. Thromb. Hemost.** 2018, **24**, 157–163. [CrossRef] [PubMed]

24. Le, D.; Brown, L.; Malik, K.; Murakami, S. Two Opposing Functions of Angiotensin-Converting Enzyme (ACE) That Links Hypertension, Dementia, and Aging. **Int. J. Mol. Sci.** 2021, **22**, 13178. [CrossRef] [PubMed]

25. Huang, S.S.; Hsu, L.J.; Chang, N.S. Functional role of WW domain-containing proteins in tumor biology and diseases: Insight into the role in ubiquitin-proteasome system. **FASEB J.** 2020, **2**, 234–253. [CrossRef] [PubMed]

26. Urbich, C.; Kaluza, D.; Frömel, T.; Knau, A.; Bennewitz, K.; Boon, R.A.; Bonauer, A.; Doebene, C.; Boeckel, J.N.; Hergenreider, E.; et al. MicroRNA-27a/b controls endothelial cell repulsion and angiogenesis by targeting semaphorin 6A. **Blood J. Am. Soc. Hematol.** 2012, **119**, 1607–1616. [CrossRef]

27. Lan, X.; Zhang, H.; Wang, Z.; Dong, W.; Sun, W.; Shao, L.; Zhang, T.; Zhang, D. Genome-wide analysis of long noncoding RNA expression profile in papillary thyroid carcinoma. **Gene** 2015, **569**, 109–117. [CrossRef]

28. Wang, S.; Chu, F.; Xia, R.; Guan, J.; Zhou, L.; Fang, X.; Dai, T.; Xie, F.; Zhang, L.; Zhou, F. LPA Maintains Innate Antiviral Immunity in a Pro-Active State via STK38l-Mediated IFR3 Ser303 Phosphorylation. **SSRN Electron. J.** 2022. [CrossRef]

29. Cacquevel, M.; Launay, S.; Castel, H.; Benchenane, K.; Cheenne, S.; Buée, L.; Moons, L.; Delacourte, A.; Carmeliet, P.; Vivien, D. Ageing and amyloid-beta peptide deposition contribute to an impaired brain tissue plasminogen activator activity by different mechanisms. **Neurobiol. Dis.** 2007, **27**, 164–173. [CrossRef]
31. Garatachea, N.; Marin, P.J.; Lucia, A. The ACE DD genotype and D-allele are associated with exceptional longevity: A meta-analysis. *Aging Res. Rev.* **2013**, *12*, 1079–1087. [CrossRef]

32. Said, R.; Jenni, R.; Boussetta, S.; Ammous, F.; Zouari, S.; Zaghib, S.; Chakroun, M.; Derouiche, A.; Chebil, M.; Ouerhani, S. Association of a common genetic variant (insertion/deletion) in ACE gene with prostate cancer susceptibility in a Tunisian population. *J. Clin. Lab. Anal.* **2022**, *36*, e24129. [CrossRef]

33. Yashin, A.I.; Wu, D.; Arbeev, K.G.; Ukraintseva, S.V. Polygenic effects of common single-nucleotide polymorphisms on life span: When association meets causality. *Rejuvenation Res.* **2012**, *15*, 381–394. [CrossRef]

34. Schächter, F.; Faure-Delanef, L.; Guénot, E.; Rouger, H.; Froguet, P.; Lesueur-Ginot, L.; Cohen, D. Genetic associations with human longevity at the APOE and ACE loci. *Nat. Genet.* **1994**, *6*, 29–32. [CrossRef]

35. Kolovou, G.; Kolovou, V.; Vasiliadis, I.; Giannakopoulou, V.; Mihas, C.; Bilianou, H.; Kollia, A.; Papadopoulou, E.; Marvaki, A.; Goumas, G.; et al. The Frequency of 4 Common Gene Polymorphisms in Nonagenarians, Centenarians, and Average Life Span Individuals. *Angiology* **2014**, *65*, 210–215. [CrossRef]

36. Atella, V.; Piano Mortari, A.; Kopinska, J.; Belotti, F.; Lapi, F.; Cricelli, C.; Fontana, L. Trends in age-related disease burden and healthcare utilization. *Aging Cell* **2019**, *18*, e12861. [CrossRef]

37. Chen, L.; He, C.Y.; Su, X.; Peng, J.L.; Chen, D.L.; Ye, Z.; Yang, D.D.; Wang, Z.X.; Wang, F.; Shao, J.Y.; et al. SPP1 rs4754 and its epistatic interactions with SPARC polymorphisms in gastric cancer susceptibility. *Gene* **2018**, *640*, 43–50. [CrossRef]

38. Durbeej, M. Laminins. *Cell Tissue Res.* **2010**, *339*, 259–268. [CrossRef]

39. Tunggal, P.; Smyth, N.; Paulsson, M.; Ott, M.C. Laminins: Structure and genetic regulation. *Microsc. Res. Tech.* **2000**, *51*, 214–227. [CrossRef]

40. Miner, J.H. Laminins and their roles on mammals. *Microsc. Res. Tech.* **2008**, *71*, 349–356. [CrossRef]

41. Oliveira, J.; Gruber, A.; Cardoso, M.; Taipa, R.; Fineza, I.; Goncalves, A.; Laner, A.; Winder, T.; Schroeder, J.; Rath, J.; et al. LAMA2 gene mutation update: Toward a more comprehensive picture of the laminin-alpha2 variome and its related phenotypes. *Hum. Mutat.* **2018**, *39*, 1314–1337. [CrossRef]

42. Miyagoe-Suzuki, Y.; Nakagawa, Y.; Takeda, S.I. Merosin and congenital muscular dystrophy. *Microsc. Res. Tech.* **2000**, *48*, 181–191. [CrossRef]

43. Chun, S.J.; Rasband, M.N.; Sidman, R.L.; Habib, A.A.; Vartanian, T. Integrin-linked kinase is required for laminin-2-induced oligodendrocyte cell spreading and CNS myelination. *J. Cell Biol.* **2003**, *163*, 397–408. [CrossRef] [PubMed]

44. Morgan, C.; Inestrosa, N.C. Interactions of laminin with the amyloid beta peptide. Implications for Alzheimer’s disease. *Braz. J. Med. Biol. Res. Res. 2001*, *34*, 597–601. [CrossRef] [PubMed]

45. De La Fuente, A.G.; Lange, S.; Silva, M.E.; Gonzalez, G.A.; Tempfer, H.; van Wijngaarden, P.; Zhao, C.; Di Canio, L.; Trost, A.; Bieler, L.; et al. Pericytes Stimulate Oligodendrocyte Progenitor Cell Differentiation during CNS Remyelination. *Cell Rep.* **2017**, *20*, 1755–1764. [CrossRef] [PubMed]

46. Hibbitts, A.J.; Koči, Z.; Kneafsey, S.; Matsiko, A.; Žilić, L.; Dervan, A.; Hinton, P.; Chen, G.; Cavanagh, B.; Dowling, J.K.; et al. Multi-Factorial Nerve Guidance Conduit Engineering Improves Outcomes in Inflammation, Angiogenesis and Large Defect Nerve Repair. *Matrix Biol.* **2022**, *106*, 34–57. [CrossRef]

47. Kittur, S.D.; Adler, W.H.; Martin, G.R.; Schapiro, M.B.; Rapoport, S.I.; Gunzler, V. Laminin concentrations in serum and cerebrospinal fluid in aging and Alzheimer’s disease. *Int. J. Dev. Neurol.* **2014**, *12*, 210–215. [CrossRef]

48. Hawkes, C.A.; Hartig, W.; Kaczka, J.; Schliebs, R.; Weller, R.O.; Nicoll, J.A.; Carare, R.O. Perivascular drainage of solutes is impaired in the ageing mouse brain and in cerebral amyloid angiopathy. *Acta Neuropathol.* **2011**, *121*, 431–443. [CrossRef]

49. Reed, M.J.; Damodarasamy, M.; Banks, W.A. The extracellular matrix of the blood–brain barrier: Structural and functional roles in health, aging, and Alzheimer’s disease. *Tissue Barriers* **2019**, *7*, 1651157. [CrossRef]

50. Komkov, A.Y.; Maschan, M.A.; Shivets, V.I.; Lebedev, Y.B. Functional analysis of polymorphic insertions of Alu retroelements in the human genome mutation update: Toward a more comprehensive picture of the laminin-alpha2 variome and its related phenotypes. *Hum. Mutat.* **2018**, *39*, 1314–1337. [CrossRef]

51. Halbleib, J.M.; Nelson, W.J. Cadherins in development: Cell adhesion, sorting, and tissue morphogenesis. *Genes Dev.* **2006**, *20*, 3199–3214. [CrossRef]

52. Shan, W.S.; Tanaka, H.; Phillips, G.R.; Arndt, K.; Yoshida, M.; Colman, D.R.; Shapiro, L. Functional cis-heterodimers of N- and R-cadherins. *J. Cell Biol.* **2000**, *148*, 579–590. [CrossRef]

53. Ramirez, T.A.; Saux, J.L.; Joy, A.; Zhang, J.; Dai, Q.; Mifflin, S.; Lindsey, M.L. Chronic and intermittent hypoxia differentially regulate left ventricular inflammatory and extracellular matrix responses. *Hypertens. Res.* **2012**, *35*, 811–818. [CrossRef]

54. Miyazaki, K.; Fujiita, T.; Ozaki, T.; Kato, C.; Kurose, Y.; Sakamoto, M.; Kato, S.; Goto, T.; Itoyama, Y.; Aoki, M.; et al. NEDL1, a novel ubiquitin–protein isopeptide ligase for dishevelled-1, targets mutant superoxide dismutase-1. *J. Biol. Chem.* **2004**, *279*, 11327–11335. [CrossRef]

55. Haouari, S.; Vourc’h, P.; Jeanne, M.; Marouillat, S.; Veyrat-Durebex, C.; Lanzaster, D.; Laumonnier, F.; Corcia, P.; Blasco, H.; Andres, C.R. The Roles of NEDD4 Subfamily of HECT E3 Ubiquitin Ligases in Neurodevelopment and Neurodegeneration. *Int. J. Mol. Sci.* **2022**, *23*, 3882. [CrossRef]

56. Li, Y.; Ozaki, T.; Kikuchi, H.; Yamamoto, H.; Ohira, M.; Nakagawara, A. A novel HECT-type E3 ubiquitin protein ligase NEDL1 enhances the p53-mediated apoptotic cell death in its catalytic activity-independent manner. *Oncogene* **2008**, *27*, 3700–3709. [CrossRef]
57. Quiroga, M.; Rodríguez-Alonso, A.; Alfonsín, G.; Rodríguez, J.J.E.; Breijo, S.M.; Chantada, V.; Figueroa, A. Protein Degradation by E3 Ubiquitin Ligases in Cancer Stem Cells. Cancers 2022, 14, 990. [CrossRef]
58. Favorov, A.V.; Andreewski, T.V.; Sudomoina, M.A.; Favorova, O.O.; Parmigiani, G.; Ochs, M.F. A Markov chain Monte Carlo technique for identification of combinatorial linkages underlying complex diseases in humans. Genetics 2005, 171, 2113–2121. [CrossRef]
59. Yazdani, U.; Terman, J.R. The semaphorins. Genome Biol. 2006, 7, 211. [CrossRef]
60. de Wit, J.; Verhaagen, J. Role of semaphorins in the adult nervous system. Prog. Neurobiol. 2003, 71, 249–267. [CrossRef]
61. Leighton, P.A.; Mitchell, K.J.; Goodrich, L.V.; Lu, X.; Pinson, K.; Scherz, P.; Skarmes, W.C.; Tessier-Lavigne, M. Defining brain wiring patterns and mechanisms through gene trapping in mice. Nature 2001, 410, 174–179. [CrossRef]
62. Loria, R.; Bon, G.; Perotti, V.; Gallo, E.; Bersani, I.; Baldassari, P.; Forru, M.; Leonetti, C.; Di Carlo, S.; Visca, P.; et al. Sema6A and Mical1 control cell growth and survival of BRAFV600E human melanoma cells. Oncotarget 2015, 6, 2779–2793. [CrossRef] [PubMed]
63. Xie, G.; Roshandel, D.; Sherva, R.; Monach, P.A.; Lu, E.Y.; Kung, T.; Carrington, K.; Zhang, S.S.; Pulit, S.L.; Ripke, S.; et al. Association of granulomatosis with polyangiitis (Wegener’s) with HLA–DPB1*04 and SEMA6A gene variants: Evidence from genome-wide analysis. Arthritis Rheum. 2013, 65, 2457–2468. [CrossRef] [PubMed]
64. Abdel-Rahman, S.M.; Preuett, B.L. Genetic predictors of susceptibility to cutaneous fungal infections: A pilot genome wide association study to refine a candidate gene search. J. Dermatol. Sci. 2012, 67, 147–152. [CrossRef] [PubMed]
65. Tian, S.; Liu, Y.; Wu, H.; Liu, H.; Zeng, J.; Choi, M.Y.; Chen, H.; Gerhard, R.; Dong, M. Genome-wide CRISPR screen identifies semaphorin 6A and 6B as receptors for Paeniclostridium sordellii toxin TsCL. Cell Host Microbe. 2020, 27, 782–792.e7. [CrossRef] [PubMed]
66. Nakanishi, Y.; Kang, S.; Kumanogoh, A. Axon guidance molecules in immunometabolic diseases. Inflamm. Regen. 2022, 42, 5. [CrossRef]
67. Segarra, M.; Ohnuki, H.; Maric, D.; Salvucci, O.; Hou, X.; Kumar, A.; Li, X.; Tosato, G. Semaphorin 6A regulates angiogenesis by modulating VEGF signaling. Blood J. Am. Soc. Hematol. 2012, 120, 4104–4115. [CrossRef]
68. Ahmad, S.; Mu, X.; Yang, F.; Greenwald, E.; Park, J.W.; Jacob, E.; Zhang, C.Z.; Hur, S. Breaching Self-Tolerance to Alu Duplex RNA Underlies MDA5-Mediated Inflammation. Cell 2018, 172, 797–810.e13. [CrossRef]
69. Lvovs, D.; Favorova, O.O.; Favorov, A.V. A polygenic approach to the study of polygenic diseases. Acta Nat. 2012, 4, 59–71. [CrossRef]
70. Peze-Heidsieck, E.; Bonnifet, T.; Znaidi, R.; Ravel-Godreuil, C.; Massiani-Beaudoin, O.; Joshi, R.L.; Fuchs, J. Retrotransposons as a Source of DNA Damage in Neurodegeneration. Front. Aging Neurosci. 2022, 13, 786897. [CrossRef]
71. Dyussenbayev, A. Age periods of human life. Adv. Soc. Sci. Res. J. 2017, 4, 258–263. [CrossRef]